US EditionPublished • loading... • Updated
GLP-1s linked to lower colon cancer mortality rates: Study
An observational study of 6,800 colon cancer patients found GLP-1 receptor agonists linked to 15.5% five-year mortality versus 37.1% in non-users, suggesting improved survival.
- On Nov. 11, 2025, UC San Diego researchers published in Cancer Investigation that colon cancer patients prescribed GLP-1 receptor agonists had 15.7% five-year mortality versus 37.1% for non-users, based on over 6,800 patients from University of California Health facilities.
- Developed for diabetes, GLP-1 receptor agonists like semaglutide and tirzepatide reduce systemic inflammation, improve insulin sensitivity, and may potentially reshape the tumor microenvironment, laboratory studies suggest.
- After adjusting for age, body mass index , cancer severity and other health factors, the team found GLP-1 use remained linked to greater survival odds using the University of California Health Data Warehouse.
- The effect raises the possibility of repurposing GLP-1 therapies, as authors describe the largest mortality reduction in patients with severe obesity as a powerful new use.
- Researchers caution that the study is observational and urge large randomized clinical trials to test whether GLP-1 drugs improve survival for obesity‑related cancers, Raphael E. Cuomo, Ph.D., said.
Insights by Ground AI
8 Articles
8 Articles
Wegovy and Ozempic tied to dramatically lower cancer deaths
GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to test whether these findings reflect a true anti-cancer mechanism.
·United States
Read Full Article
GLP-1 drugs linked to improved survival in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.
·United States
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
